Cotinine impacts sensory processing in DBA/2 mice through changes in the conditioning amplitude.

Area of Science:

• Neuroscience
• Pharmacology

Background:

• Cotinine, a nicotine metabolite, shows potential in improving cognitive functions and correcting sensory gating deficits in animal models.
• DBA/2 mice exhibit spontaneous deficits in hippocampal sensory inhibition, mirroring those seen in schizophrenia patients.

Purpose of the Study:

• To investigate the acute and chronic effects of cotinine on sensory inhibition in DBA/2 mice using the P20-N40 EEG paradigm.
• To explore the specific nicotinic receptor subtypes involved in cotinine's modulation of sensory inhibition.

Main Methods:

• DBA/2 mice were administered varying doses of cotinine (0.1–3.3 mg/kg) acutely and daily for 7 days.
• Hippocampal EEG recordings (CA3 region) were used to assess the P20-N40 sensory inhibition paradigm.
• Nicotinic receptor blockade (α4β2 and α7) was employed to determine receptor involvement.

Main Results:

• Acute cotinine administration (0.1, 0.33, 1.0 mg/kg) significantly increased conditioning amplitude.
• Blockade of α4β2 and α7 nicotinic receptors attenuated cotinine's effect on conditioning amplitude.
• Chronic cotinine administration (0.33, 3.3 mg/kg) also increased conditioning amplitude, with evidence of carry-over effects.

Conclusions:

• Cotinine modulates sensory inhibition in DBA/2 mice, primarily through α4β2 nicotinic receptors and potentially α7 nicotinic receptors.
• Despite modulating sensory inhibition, cotinine is unlikely to be a therapeutic agent for sensory inhibition deficits in schizophrenia.